CareDx Inc. (CDNA) stock reached a 52-week high of $55.21, trading at $55.09 — just 1% below its peak — on Wednesday following the company’s second-quarter 2026 results that topped analysts’ expectations across the board.
The biotech diagnostics firm reported adjusted earnings per share of $0.37, significantly beating the $0.23 consensus estimate. Total revenue came in at $131.9 million, surpassing the anticipated $113.82 million, while testing revenue alone totaled $99.9 million.
On a year-over-year basis, total revenue grew 52% and testing revenue surged 61%, underscoring accelerating demand for the company’s transplant diagnostic offerings.
The strong quarter has sent shares up 262% over the past year, yet the stock still trades well above InvestingPro’s fair-value estimate of $41.06. The company’s P/E ratio stands at 25.44 with a PEG ratio of 0.22, and it earned a perfect Piotroski score of 9, reflecting robust fundamentals.
Wall Street reaction was split. Canaccord Genuity initiated coverage with a buy rating and a $65 price target, citing CareDx’s leadership position in transplant diagnostics. H.C. Wainwright, meanwhile, reiterated a neutral rating with a $46 price target following the quarterly results.
Shares continue to trade at a premium to consensus fair value even as growth metrics remain strong, raising questions about whether further upside is priced in or whether the market is rewarding sustained execution.
